Journal of Thrombosis and Thrombolysis

, Volume 20, Issue 2, pp 105–112

Antiphospholipid Antibodies in Young Adults with Stroke


DOI: 10.1007/s11239-005-3204-6

Cite this article as:
Brey, R.L. J Thromb Thrombolysis (2005) 20: 105. doi:10.1007/s11239-005-3204-6


Background. Antiphospholipid antibodies have been associated with a clinical syndrome consisting thrombosis and recurrent, unexplained fetal loss.

Methods. The literature pertaining to stroke associated with antiphospholipid antibodies, with emphasis on stroke in young adults, was reviewed.

Results. Antiphospholipid antibodies are an independent risk factor for stroke in young adults in five of six studies. Multiple antiphospholipid specificities or the Lupus Anticoagulant were tested in addition to anticardiolipin antibody in these studies. In the single study that found no increased risk for stroke, only anticardiolipin antibody was tested. Only one of these studies evaluated for risk of recurrent stroke in young adults with antiphospholipid antibodies and found it to be increased. No treatment trials have been conducted in young adults with antiphospholipid antibodies and stroke. In the single treatment trial comparing aspirin and low-INR producing doses of warfarin to prevent recurrent stroke, both were found to be equally effective.

Conclusions. Antiphospholipid antibodies, particularly Lupus Anticoagulant, is an independent risk factor for first and possibly recurrent ischemic stroke in young adults. The best therapeutic strategy for preventing antiphospholipid antibody-associated recurrent stroke is not clear.

Key Words

antiphospholipid antibodiesanticardiolipin antibodylupus anticoagulantantiphospholipid syndromecerebral ischemia

Copyright information

© Springer Science + Business Media, Inc. 2005

Authors and Affiliations

  1. 1.University of Texas Health Science Center at San AntonioSan AntonioUSA